1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Spectrum Pharma gets 'Hanmi-downs' to boost oncology pipeline

 
• By Ian Haydock

Spectrum Pharmaceuticals, best known perhaps for its development of the targeted anticancer treatment, Zevalin (ibritumomab tiuxetan), has bolstered its oncology pipeline through the acquisition of selected rights to Hanmi Pharmaceuticals’ long-acting granulocyte colony-stimulating factor product SPI-2012 (HM10460A). Spectrum has indicated that there are signs of improved activity in the novel formulation over conventional versions of the drug.

Spectrum Pharmaceuticals, best known perhaps for its development of the targeted anticancer treatment, Zevalin (ibritumomab tiuxetan), has bolstered its oncology pipeline through the acquisition of selected rights to Hanmi Pharmaceuticals’ long-acting granulocyte colony-stimulating factor product SPI-2012 (HM10460A). Spectrum has indicated that there are signs of improved activity in the novel formulation over conventional versions of the drug.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 
• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Boehringer Boss Talks Tariffs And State Of Play In The US

 
• By Kevin Grogan

The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By Joseph Haas

With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.

More from Therapeutic Category

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.